IGM Biosciences Inc.

(NASDAQ:IGMS) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

IGM Biosciences Inc is a biotechnology company involved in the development of engineered IgM antibodies for the treatment of cancer patients. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

Contact Information

Website: www.igmbio.com
Email: info@igmbio.com
Main Phone: +1 650 965-7873
Address: 325 East Middlefield Road
State: CA
City / Town: Mountain View
Country: US
Postal Code: 94043

Issuer Information

Exchange: NGS
CEO: Fred Schwarzer
Employees: 64
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A